Limitations, agreements, and source contact

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma · Source last updated 2025-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

csirard@leaptx.com

organization

Leap Therapeutics, Inc.

phone

+1-617-714-0360

title

Cynthia Sirard, MD, Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice